Mepolizumab therapy decreases epithelial-derived cytokine concentrations in exhaled breath condensates from patients with severe eosinophilic asthma

Clin Exp Allergy. 2023 Aug;53(8):846-849. doi: 10.1111/cea.14316. Epub 2023 Apr 13.

Authors

Aleksandra Likońska¹, Alicja Nowak-Jurek¹, Adrian Gajewski¹, Monika Antczak-Marczak¹, Karolina Frachowicz-Guerreiro¹, Aleksandra Wardzyńska¹, Maciej Chałubiński¹

Affiliation

¹ Department of Immunology and Allergy, Chair of Pulmonology, Rheumatology and Clinical Immunology, Medical University of Lodz, Poland, Lodz, Poland.

PMID: 37055938
DOI: 10.1111/cea.14316

No abstract available

Keywords: IL-25; IL-33; anti-IL-5 treatment; asthma; exhale breath condensates; mepolizumab; periostin.

Publication types

Letter

MeSH terms

Anti-Asthmatic Agents* / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Asthma* / diagnosis
Asthma* / drug therapy
Cytokines
Humans
Pulmonary Eosinophilia*

Substances

mepolizumab
Cytokines
Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized